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Morbidity and mortality from asthma in the Western world is increasing despite effective prophylactic drugs. 
Beta agonists are increasingly considered causal; while under-prescribing of inhaled steroids or other anti- 
inflammatories are accepted as causes for the problems, but the role of non-compliance with inhaled asthma 
therapy is rarely mentioned. Using a novel electromechanical counter MD1 actuations have been recorded in 
three small (9-l 1 patients), short (2-3 weeks) studies. When aware compliance with prescribed inhaled steroids 
was under scrutiny, six patients were fully compliant, two took just 70% ofthe prescibed regimen, but two did not 
follow the prescribed regimen at all. When unware of scrutiny, six out of 11 were compliant but five patients were 
estimated as taking less than 30-S 1% of the prescribed dose of inhaled steroid. When asked to monitor rescue 
bronchodilator usage patients consistently under-recorded. Under-use as well as under prescription of inhaled 
steroids and under-estimation (8) of&agonists use may be contributory factors to the present increase in asthma 
mortality and morbidity. These potential problems of poor compliance need larger scale studies to show how and 
if behaviour can be altered to improve compliance. 
Introduction 
There is concern over the increasing morbidity and 
mortality from asthma in the Western world, particu- 
larly with the role of &agonists and the apparent 
failure of inhaled prophylactic agents (1). One 
explanation for this may be that inhaled steroids were 
shown to be comparatively ineffective in the treatment 
of asthma (2) on an ‘intention to treat’ basis but 
obviously effective in patients who were actively taking 
them (3). 
Assessing compliance in patients with asthma on 
inhaled therapy is difficult (4) although one method is 
to assess therapeutic response with measurement of 
peak flow by the patient twice daily at home (5) but 
is dependent upon patient cooperation and is less 
satisfactory in clinical trials with new compounds. In 
an attempt to objectively assess metered dose inhaler 
use, an electro-mechanical counter attached to the 
plastic shell of the standard MD1 was developed (6). 
Actuations are counted by means of a microswitch 
that is closed each time the cannister is depressed to 
discharge the aerosol. The count is displayed on a 
liquid crystal display that can be made blind to the 
patient by means of a plastic cover. The counter may 
be pre-set to ignore actuations within a given refrac- 
tory period, which in these studies was 3 s, that is 
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a second actuation within 3 s was not recorded. The 
device is powered by a 3V lithium -manganese di- 
oxide battery and can be reset to 0 for further use 
following sterilization, weighs 7.5 g, and measures 
27x 12x7mm(seePlate 1). 
Methods 
VALIDATION OF THE COUNTER DEVICE 
The initial validation was determined by discharg- 
ing an MD1 into the air and contemporaneously press- 
ing a tally counter. To take account of the refractory 
period of 3 s there was a minimum of 5 s between 
actuations. Five MDIs for each of five counters were 
discharged until empty. The aerosol counter reading 
and that of the tally agreed within 1% (6). 
All patients were recruited from specialist asthma 
clinics held at Guy’s and Lewisham hospitals. All 
patients were considered by the consultant supervising 
the clinic to have a diagnosis compatible with asthma, 
although not all patients had total reversibility. The 
studies were approved by the Ethics committees of the 
two hospitals. 
STUDY I 
Ten patients (six male, four female, age range 23-54 
years, mean 38 years) on regular MD1 inhaled steroids 
were invited to take part in this 2-week study to vali- 
date the counter device against the diary card which 
they used to record inhaler use. The patients were 
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Plute I 
issued with their present strength of inhaled steroid 
together with the counter and the patient asked to 
continue their prescribed regime. They were asked to 
record their daily use of inhaled steroid on a diary 
card and MD1 inhaler technique was reviewed with 
each patient emphasizing a minimum of 10 s between 
actuations. The patients in this study were aware that 
the device had a counter but the actual liquid crystal 
display was obscured by use of a plastic cover. 
At the end of the study the patients returned the 
counter, MD1 and diary card. The prescribed number 
of inhalations were compared with the self-reported 
diary card and the actuations recorded by the counter. 
STUDY 2 
A further I I patients (three male, eight female, age 
range 14-55 years, mean 32 years) were recruited to 
this study which was similar in format to the first but 
lasted 3 weeks. The patients were not directly told that 
the new device incorporated an electro-mechanical 
counter but rather that it was a prototype inhaler 
containing their usual inhaled corticosteroid. Patients 
were taught appropriate MD1 techniques. These 
patients were also asked to record simple symptom 
scores and morning and night peak flow rates on a 
Wright’s mini peak flow meter to simulate a normal 
clinical trial procedure. At the end of the study the 
patients returned the counters, MD1 and diary card. 
Analysis was similar to study 1. 
STUDY 3 
Nine patients (three male, six female, age range 
14-65 years, mean 34 years) who took regular inhaled 
steroids but were taking rescue&agonists in addition, 
were invited to take part in this study which lasted 2 
weeks. The patients were issued with a salbutamol 
MD1 for rescue medication and were informed that 
there was a counter attached to the device but this was 
obscured from view. Their inhaler technique was 
checked. They were told that the aim of the study was 
to see how able they were at remembering their rescue 
medication use and they were asked to note its usage at 
the end of each day. Patients were encouraged to only 
use the single modified counter inhaler as rescue, but 
inevitably there could have been patients who some- 
times used other inhalers. At the end of the 2-week 
study the patients returned the inhaler with their daily 
recorded use of salbutamol for rescue on a diary card. 
Results 
STUDY I 
Full results of prescribed, self-reporting and counter 
are shown in Table 1. There is no statistical difference 
(Student’s paired t-test) between self-reporting and 
prescribed doses, between counter recording and pres- 
cribed doses and counter recording and reported use. 
However, hidden within the statistical result it can be 
seen (Table 1) that six patients were fully compliant 
and two patients were less compliant with the pres- 
cribed dose of inhaled aerosol but reported accurately 
their under-use of treatment. Two patients show inter- 
esting variations. Patient number 1 self-reported the 
correct number of prescribed doses though by counter 
recording was clearly non-compliant actually taking 
only a quarter of the prescribed dose. Patient 10, 
however, honestly reported the non-use of the inhaled 
steroid, the counter showing him taking less than a 
fifth of the prescribed dose. 
STUDY 2 
The full results are outlined in Table 2. Statistical 
analysis using Student’s paired r-test shows that in 
these patients, who were unaware of the counter, there 
is a statistical difference between the counted use of 
drug and the self-reported administration (P~0.05). 
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Table I Results comparing prescribed BDP, self-reported taking of BDP and the electromechanical counter as inhalations of 
BDP in patients who were aware of the counter 
Patient No. Prescribed (P) Self-reported (S) Counter(C) Compliance C/P% 
I 56 56 15 26.8 
2 112 96 118 105.4 
3 84 78 87 103.6 
4 56 54 53 94.6 
5 336 258 240 71.4 
6 54 44 39 72.2 
7 108 104 106 98.1 
8 56 52 52 92.9 
9 20 19 18 90.0 
10 28 4 6 21.4 
Mean (95% confidence interval) 91(29,1-152.9) 76.5(28+124.6) 73.4(25.9-120.9) 78(57-98.3) 
Table 2 Results comparing prescribed BDP, self-reported taking of BDP and the electromechanical counter as inhalations of 
BDP in patients who were unaware of the counter 
Patient No. Prescribed (P) Self-reported (S) Counter(C) Compliance C/P% 
1 112 106 106 94.6 
2 164 164 148 90.2 
3 210 210 210 I00~00 
4 123 123 122 99.2 
5 120 120 41 34.2 
6 84 82 42 50.0 
7 160 160 137 85.6 
8 164 164 74 45.1 
9 164 135 82.3 
10 164 55 55 33.5 
II 122 122 63 51.6 
Mean (95% confidence interval) 144~3(121+~166~8) 129(97+161.6) 103(68+137.1) 69.7(52.6-86.8) 
Also there is a significant difference between the 
counter recording and the prescribed therapy but there 
is no significant difference between prescribed and self- 
reported. Individual analysis of the 11 patients shows 
that six accurately followed the prescribed regime 
assessed by counter recordings. The other five patients 
had a considerably lower level of compliance, at 
around the 50% level on counter assessment, with four 
of them self-reporting doses, however, in accordance 
with the prescribed regime. 
STUDY 3 
Compliance with inhaled therapy even in closely 
controlled clinical studies in asthma has been poorly 
investigated because of the difficulties of designing 
accurate and precise techniques of assessment. 
Cannister weighing has a number of potential inaccur- 
acies, particularly rescue bronchodilatation when 
numerous inhalers are used and is always retrospec- 
tive. Direct measurement of biological specimens such 
as urine salbutamol levels give only an indication of 
therapy on the day of use, are expensive and time 
consuming (8). 
The results of this study are shown in Table 3. There These studies using an electromechanical counter 
is a statistically significant difference between counter are an attempt to look at adherence to prescribed 
recording and self-reported use of rescue broncho- regimes of inhaled steroids and also patients’ ability to 
dilator (P < 0.015). The results almost invariably show remember rescue bronchodilator usage on a daily 
an under-reporting of the remembered actual use of basis. The counter was shown to be reliable, repro- 
rescue bronchodilator. ducible in the laboratory situation and capable of 
Discussion 
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Tub/e 3 Results comparing self-reported use of rescue bronchodilator drug with counter to 
inhalations of sulbutamol 
Patient No. Self-reported (S) Counter(C) Accuracy S/C 
1 172 216 80 
2 52 59 88 
3 174 204 75 
4 5 7 71 
5 90 107 84 
6 78 97 80 
7 68 81 84 
8 18 55 33 
9 32 22 145 
Mean (95% confidence interval) 76.6(32.1-120.9) 94.2(41,2-147.3) 83,5(62.6-104.3) 
identifying actuation use. Definitions of good and 
poor compliance are arbitrary but patients taking over 
80% of prescribed therapy may be classed as ‘good’ 
compliers, 7&80% adequate compliers, with patients 
taking less than half of the medication as poorly 
compliant (9). The majority of patients who were 
aware of the counter were compliant, taking more 
than 70% of the prescribed medication. The remaining 
two behaved in different fashions, one recording his 
poor compliance, the other despite kno?ving he was 
under scrutiny reported use in excess of counter 
measurements. 
Not surprisingly when patients were unaware that 
their behaviour would be scrutinized fewer patients 
followed the physician’s prescribed regime. Four of the 
five who were taking less than 50% of the prescribed 
regime by the counter reported good compliance. 
Patients who were aware of the counter but also asked 
to record their use of rescue bronchodilator were 
unable to do so accurately. The fact that patients may 
have used other inhalers would increase their degree of 
under-estimation. This finding is disturbing as clinical 
trials of new prophylactic drugs rely on recording of 
rescue-bronchodilator as an indication of trial drug 
efficacy. 
These results show a marked variation in thera- 
peutic compliance from complete adherence to less 
than a quarter of the prescribed doses of inhaled 
prophylactic being taken. Obviously the study as- 
sumes the patients required the prescribed regime, did 
not ‘test fire’ all their ‘inhalations’ or just actuate the 
inhaler in the waiting room of the outpatients. A device 
using a real time clock (10) suggested similar problems 
of poor compliance but the patients were asked to 
take medication four times per day rather than twice a 
day. Our studies were undertaken over short periods 
of time (2-3 weeks) so it is unlikely patients were 
consistently compliant or non-compliant and were not 
affected by any improvement in symptoms with conse- 
quent reduction in treatment, particularly inhaled 
steroids. 
The patients were studied in hospital specialist 
clinics where there were educational programmes and 
respiratory technician support, so these results are dis- 
appointing and possibly under-estimate the problems 
of non-adherence to inhaled medication in asthma, 
particularly inhaled steroids. Failure to remember 
rescue MD1 bronchodilator usage is understandable, 
but failure to adhere to a regime of inhaled steroids 
when aware that their behaviour is under scrutiny 
requires further investigation. 
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